Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown
The major market for chronic heart failure — until recently an indication without a single approved therapy — has evolved into a horse race in recent months …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
